Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

STRYKER CORPORATION

(SYK)
  Report
Delayed Nyse  -  04:04 2022-12-02 pm EST
243.11 USD   +0.97%
12/02Barclays Adjusts Price Target on Stryker to $257 From $239, Maintains Overweight Rating
MT
12/01Transcript : Stryker Corporation Presents at 5th Annual Evercore ISI HealthCONx Conference 2022, Dec-01-2022 08:50 AM
CI
11/15Stryker Corp : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Stryker Receives FDA Clearance for OptaBlate Bone Tumor Ablation System

09/20/2022 | 08:07am EST

Stryker announced that its OptaBlate bone tumor ablation system (OptaBlate) received 510(k) clearance from the U.S. Food and Drug Administration. The addition of the OptaBlate technology to Stryker's Interventional Spine (IVS) portfolio expands on its core competencies in vertebral augmentation and radiofrequency ablation and completes its portfolio of treatment options for metastatic vertebral body fractures. As Stryker's first Interventional Oncology technology, OptaBlate optimizes all aspects of the procedure—from set-up to ablation.

Featuring four probes and Stryker's unique and patented microinfusion technology, OptaBlate allows physicians to easily customize their procedure and reduce ablation time by three minutes. Specific key features of the system include: Treatment of two vertebral body levels at once using a bipedicular approach, Quicker, more consistent ablation, Microinfusion technology, which keeps the zone hydrated, reducing impedance errors and preventing charring.


ę S&P Capital IQ 2022
All news about STRYKER CORPORATION
12/02Barclays Adjusts Price Target on Stryker to $257 From $239, Maintains Overweight Rating
MT
12/01Transcript : Stryker Corporation Presents at 5th Annual Evercore ISI HealthCO..
CI
11/15Stryker Corp : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial ..
AQ
11/14Stryker opens the OR of the Future for customers to experience tomorrow's OR today
PR
11/14Stryker Opens the OR of the Future for Customers to Experience Tomorrow's OR
CI
11/04Insider Sell: Stryker
MT
11/03Stryker to participate in the 5th Annual Evercore ISI HealthCONx Conference
GL
11/02DA Davidson Adjusts Stryker Price Target to $250 From $260, Maintains Buy Rating
MT
11/01Uber, Pfizer rise; Catalent, Stryker fall
AQ
11/01STRYKER CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS O..
AQ
More news
Analyst Recommendations on STRYKER CORPORATION
More recommendations
Financials (USD)
Sales 2022 18 201 M - -
Net income 2022 2 568 M - -
Net Debt 2022 10 484 M - -
P/E ratio 2022 35,6x
Yield 2022 1,15%
Capitalization 92 000 M 92 000 M -
EV / Sales 2022 5,63x
EV / Sales 2023 5,23x
Nbr of Employees 46 000
Free-Float 98,2%
Chart STRYKER CORPORATION
Duration : Period :
Stryker Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends STRYKER CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Last Close Price 243,11 $
Average target price 237,67 $
Spread / Average Target -2,24%
EPS Revisions
Managers and Directors
Kevin A. Lobo Chairman, President & Chief Executive Officer
Glenn S. Boehnlein Chief Financial Officer & Vice President
Alan Douville Chief Information Officer & Vice President
Dana S. McMahon Chief Compliance Officer & Vice President
Howard E. Cox Director-Emeritus
Sector and Competitors
1st jan.Capi. (M$)
STRYKER CORPORATION-9.09%92 000
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.-7.57%15 273
SMITH & NEPHEW PLC-15.77%11 604
INSPIRE MEDICAL SYSTEMS, INC.4.10%6 919
AXONICS, INC.25.61%3 484
ENOVIS CORPORATION-27.36%3 110